Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel...

por Bondarenko, Igor, Gladkov, Oleg A, Elsaesser, Reiner, Buchner, Anton, Bias, Peter
Publicado 2013

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

por Bondarenko, Igor M, Ingrosso, Antonella, Bycott, Paul, Kim, Sinil, Cebotaru, Cristina L
Publicado 2015

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

por Volovat, Constantin, Bondarenko, Igor M, Gladkov, Oleg A, Elsässer, Reiner, Buchner, Anton, Bias, Peter, Müller, Udo
Publicado 2015

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference...

por Kahan, Zsuzsanna, Grecea, Daniela, Smakal, Martin, Tjulandin, Sergei, Bondarenko, Igor, Perjesi, Luca, Illes, Andras, Horvat-Karajz, Karoly, Aradi, Ildiko
Publicado 2019

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin(®)), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non...

por Reinmuth, Niels, Bryl, Maciej, Bondarenko, Igor, Syrigos, Kostas, Vladimirov, Vladimir, Zereu, Manuela, Bair, Angel H., Hilton, Fiona, Liau, Katherine, Kasahara, Kazuo
Publicado 2019

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

por Belani, Chandra P, Yamamoto, Nobuyuki, Bondarenko, Igor M, Poltoratskiy, Artem, Novello, Silvia, Tang, Jie, Bycott, Paul, Niethammer, Andreas G, Ingrosso, Antonella, Kim, Sinil, Scagliotti, Giorgio V
Publicado 2014

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of...

por Aapro, Matti, Karthaus, Meinolf, Schwartzberg, Lee, Bondarenko, Igor, Sarosiek, Tomasz, Oprean, Cristina, Cardona-Huerta, Servando, Hansen, Vincent, Rossi, Giorgia, Rizzi, Giada, Borroni, Maria Elisa, Rugo, Hope
Publicado 2016

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Dou...

por Li, Rubi K., Tokunaga, Eriko, Adamchuk, Hryhoriy, Vladimirov, Vladimir, Yanez, Eduardo, Lee, Keun Seok, Bondarenko, Igor, Vana, Alicia, Hilton, Fiona, Ishikawa, Tomofumi, Tajima, Kentaro, Lipatov, Oleg
Publicado 2022

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐control...

por Daniel, Davey, Kuchava, Vladimer, Bondarenko, Igor, Ivashchuk, Oleksandr, Reddy, Sreekanth, Jaal, Jana, Kudaba, Iveta, Hart, Lowell, Matitashvili, Amiran, Pritchett, Yili, Morris, Shannon R., Sorrentino, Jessica A., Antal, Joyce M., Goldschmidt, Jerome
Publicado 2021

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equiv...

por Xu, Binghe, Zhang, Qingyuan, Sun, Tao, Li, Wei, Teng, Yue’e, Hu, Xichun, Bondarenko, Igor, Adamchuk, Hryhoriy, Zhang, Liangming, Trukhin, Dmytro, Wang, Shusen, Zheng, Hong, Tong, Zhongsheng, Shparyk, Yaroslav, Wang, Qingyu
Publicado 2021

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (...

por Syrigos, Konstantinos, Abert, Istvan, Andric, Zoran, Bondarenko, Igor N, Dvorkin, Mikhail, Galic, Kristina, Galiulin, Rinat, Kuchava, Vladimer, Sriuranpong, Virote, Trukhin, Dmytro, Zhavrid, Edvard, Fu, Dongyue, Kassalow, Laurent M, Jones, Stephanie, Bashir, Zahid
Publicado 2021

Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial

por Leo, Angelo Di, Jerusalem, Guy, Petruzelka, Lubos, Torres, Roberto, Bondarenko, Igor N., Khasanov, Rustem, Verhoeven, Didier, Pedrini, José L., Smirnova, Iya, Lichinitser, Mikhail R., Pendergrass, Kelly, Malorni, Luca, Garnett, Sally, Rukazenkov, Yuri, Martin, Miguel
Publicado 2013

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology

por Garnett, Sally Anne, Martin, Miguel, Jerusalem, Guy, Petruzelka, Lubos, Torres, Roberto, Bondarenko, Igor N., Khasanov, Rustem, Verhoeven, Didier, Pedrini, José L., Smirnova, Iva, Lichinitser, Mikhail R., Pendergrass, Kelly, Lindemann, Justin P. O., Di Leo, Angelo
Publicado 2013

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast...

por Finn, Richard S., Boer, Katalin, Bondarenko, Igor, Patel, Ravindranath, Pinter, Tamas, Schmidt, Marcus, Shparyk, Yaroslav V., Thummala, Anu, Voitko, Nataliia, Bananis, Eustratios, McRoy, Lynn, Wilner, Keith, Huang, Xin, Kim, Sindy, Slamon, Dennis J., Ettl, Johannes
Publicado 2020

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from...

por Finn, Richard S., Crown, John P., Ettl, Johannes, Schmidt, Marcus, Bondarenko, Igor M., Lang, Istvan, Pinter, Tamas, Boer, Katalin, Patel, Ravindranath, Randolph, Sophia, Kim, Sindy T., Huang, Xin, Schnell, Patrick, Nadanaciva, Sashi, Bartlett, Cynthia Huang, Slamon, Dennis J.
Publicado 2016

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer

por Socinski, Mark A., Waller, Cornelius F., Idris, Tazeen, Bondarenko, Igor, Luft, Alexander, Beckmann, Katrin, Vishweswaramurthy, Ashwini, Loganathan, Subramanian, Donnelly, Charles, Hummel, Matthew A., Shapiro, Roxann, Woods, Melody, Rao, Anita, Nayak, Vivek G, Ranganna, Gopinath, Barve, Abhijit
Publicado 2021

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomize...

por Turner, Nicholas, Dent, Rebecca A., O’Shaughnessy, Joyce, Kim, Sung-Bae, Isakoff, Steven J., Barrios, Carlos, Saji, Shigehira, Bondarenko, Igor, Nowecki, Zbigniew, Lian, Qinshu, Reilly, Sarah-Jayne, Hinton, Heather, Wongchenko, Matthew J., Kovic, Bruno, Mani, Aruna, Oliveira, Mafalda
Publicado 2021

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind st...

por Pegram, Mark D., Bondarenko, Igor, Zorzetto, Marina Moreira Costa, Hingmire, Sachin, Iwase, Hirotaka, Krivorotko, Petr V., Lee, Keun Seok, Li, Rubi K., Pikiel, Joanna, Aggarwal, Rajesh, Ewesuedo, Reginald, Freyman, Amy, Li, Ray, Vana, Alicia, Yin, Donghua, Zacharchuk, Charles, Tan-Chiu, Elizabeth
Publicado 2018

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

por Gümüş, Mahmut, Chen, Chieh‐I, Ivanescu, Cristina, Kilickap, Saadettin, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, Turk, Haci M., Cicin, Irfan, Harnett, James, Mastey, Vera, Naumann, Ulrike, Reaney, Matthew, Konidaris, Gerasimos, Sasane, Medha, Brady, Keri J. S., Li, Siyu, Gullo, Giuseppe, Rietschel, Petra, Sezer, Ahmet
Publicado 2022

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1...

por de Castro, Gilberto, Kudaba, Iveta, Wu, Yi-Long, Lopes, Gilberto, Kowalski, Dariusz M., Turna, Hande Z., Caglevic, Christian, Zhang, Li, Karaszewska, Boguslawa, Laktionov, Konstantin K., Srimuninnimit, Vichien, Bondarenko, Igor, Kubota, Kaoru, Mukherjee, Rinee, Lin, Jianxin, Souza, Fabricio, Mok, Tony S.K., Cho, Byoung Chul
Publicado 2023